EHA 2021

Lymphoma

Immuno-oncology agents are effective in treating classic Hodgkin’s lymphoma

Presented By

Dr Marc André, Centre Hospitalier Universitaire UCL Namur, Belgium

Trial

CheckMate 205; KEYNOTE-087

Conference

EHA 2021

5 August, 2021 12:26

MATRix with ASCT: best long-term survival for primary CNS lymphoma

Presented By

Dr Gerald Illerhaus, Klinikum der Landeshauptstadt Stuttgart, Germany

Trial

Phase 2, IELSG32

Conference

EHA 2021

5 August, 2021 12:05

Naratuximab emtansine + rituximab safe and effective in diffuse large B-cell lymphoma

Presented By

Dr Moshe Yair Levy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, USA

Conference

EHA 2021

5 August, 2021 11:55

The journey ahead for CAR T-cell therapy in r/r follicular lymphoma

Presented By

Dr Bastian von Tresckow, University Hospital Essen, Germany

Trial

ZUMA-5; ELARA

Conference

EHA 2021

5 August, 2021 11:47

ZUMA-5 vs SCHOLAR-5: Axicabtagene ciloleucel significantly improves FL outcome

Presented By

Prof. John Gribben, Barts Cancer Institute, UK

Trial

ZUMA-5; SCHOLAR-5

Conference

EHA 2021

5 August, 2021 11:18

Promising chemo-free treatment options in r/r DLBCL

Presented By

Prof. Marco Ladetto, University del Piemonte Orientale, Italy

Trial

LOTIS-2

Conference

EHA 2021

5 August, 2021 11:17

Leukaemia

Sabatolimab achieved durable responses in patients with high-risk MDS and AML

Presented By

Prof. Andrew Wei, Alfred Hospital and Monash University, Australia

Conference

EHA 2021

5 August, 2021 14:27

Final analysis of EURO-SKI: primary endpoints met in chronic myeloid leukaemia

Presented By

Prof. Susanne Saußele, Heidelberg University, Germany

Trial

EURO-SKI

Conference

EHA 2021

5 August, 2021 14:13

Favourable outcomes with zanubrutinib versus ibrutinib in patients with r/r CLL

Presented By

Prof. Peter Hillmen, University of Leeds, UK

Trial

Phase 3, ALPINE

Conference

EHA 2021

5 August, 2021 14:08

Oral azacitidine improves overall survival in patients with acute myeloid leukaemia

Presented By

Prof. Hartmut Döhner, Universitätsklinikum Ulm, Germany

Trial

Phase 2, QUAZAR AML-001

Conference

EHA 2021

5 August, 2021 13:59

Reduced-intensity conditioning ASCT is effective in older patients with AML

Presented By

Prof. Nigel Russell, Guy's Hospital, UK

Trial

AML16; AML18

Conference

EHA 2021

5 August, 2021 13:55

ELEVATE-TN: Acalabrutinib shows long-term efficacy in chronic lymphocytic leukaemia

Presented By

Dr Jeff Sharman, US Oncology Network, USA

Trial

Phase 3, ELEVATE-TN

Conference

EHA 2021

5 August, 2021 13:50

ELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety versus ibrutinib

Presented By

Prof. Peter Hillmen, St James’s University Hospital, UK

Trial

Phase 3, ELEVATE-RR

Conference

EHA 2021

5 August, 2021 13:43

Fixed 12 cycles and MRD-guided venetoclax consolidation effective in CLL

Presented By

Dr Mark-David Levin, Albert Schweitzer Hospital, the Netherlands

Trial

Phase 2, HOVON 139/GiVe

Conference

EHA 2021

5 August, 2021 13:38

GLOW: Ibrutinib + venetoclax showed superior PFS as first-line CLL treatment

Presented By

Prof. Arnon Kater, Amsterdam University Medical Centres, the Netherlands

Trial

Phase 2, GLOW

Conference

EHA 2021

5 August, 2021 13:33

Myeloma and Myelofibrosis

Novel targets in myelofibrosis: overview of emergent therapies

Presented By

Prof. Francesco Passamonti, University of Insubria, Italy

Trial

PERSIST; SIMPLIFY; BOREAS

Conference

EHA 2021

5 August, 2021 14:54

Immune therapy of multiple myeloma

Presented By

Prof. Noopur Raje, Massachusetts General Cancer Center, USA

Trial

KarMMA; CARTITUDE-1; UNIVERSAL

Conference

09:56:04pm> from conference

5 August, 2021 14:49

MAIA results confirm superior efficacy of daratumumab with standard-of-care

Presented By

Prof. Thierry Facon, University of Lille, France

Trial

Phase 3, MAIA

Conference

EHA 2021

5 August, 2021 14:46

ANDROMEDA: Addition of daratumumab showed superior efficacy in patients with AL amyloidosis

Presented By

Prof. Efstathios Kastritis, National and Kapodistrian University of Athens, Greece

Trial

Phase 3, ANDROMEDA

Conference

EHA 2021

5 August, 2021 14:31

Thrombotic and Thrombocytopenic Disorders including COVID-19 related

Acquired TTP: new treatments and updated guidelines

Presented By

Dr María Mingot-Castellano, Hospital Universitario Virgen del Rocío, Spain

Trial

HERCULES; TITAN

Conference

EHA 2021

5 August, 2021 15:25

Maternal screening to prevent foetal and neonatal alloimmune thrombocytopenia

Presented By

Prof. Dick Oepkes, Leiden University Medical Centre, the Netherlands

Conference

EHA 2021

5 August, 2021 15:21

Fostamatinib effectively increased platelet counts in immune thrombocytopenic purpura

Presented By

Prof. Waleed Ghanima, University of Oslo, Norway

Trial

Phase 3, FIT-1,-2,-3

Conference

EHA 2021

5 August, 2021 15:16

Physiopathology of coagulopathy in haematological malignancies and COVID-19

Presented By

Prof. Marcel Levi, Amsterdam University Medical Centre, the Netherlands

Conference

EHA 2021

5 August, 2021 15:11

Haemostatic abnormalities are associated with mortality in COVID-19

Presented By

Dr Yu Hu, Wuhan Union Hospital, China

Conference

EHA 2021

5 August, 2021 15:07

Mechanisms of COVID-19 vaccine-induced thrombotic thrombocytopenia

Presented By

Prof. Andreas Greinacher, Universitätsmedizin Greifswald, Germany

Conference

EHA 2021

5 August, 2021 15:03

COVID-19 vaccine-induced immune thrombotic thrombocytopenia: discovery and diagnosis

Presented By

Prof. Sabine Eichinger, Medical University Hospital of Vienna, Austria

Conference

EHA 2021

5 August, 2021 14:58

Haemoglobinopathies